Novartis AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVS research report →
About the company
Novartis AG is a global healthcare enterprise dedicated to the discovery, development, production, and distribution of medical products across the world. The company operates through two main divisions: Innovative Medicines and Sandoz. Its Innovative Medicines segment provides prescription drugs to both patients and healthcare professionals, addressing a wide array of therapeutic areas such as ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory health, cardiovascular conditions, renal disorders, and metabolic diseases.
- CEO
- Vasant Narasimhan
- IPO
- 1996
- Employees
- 75,883
- HQ
- Basel, CH
Price Chart
- Market Cap
- $284.53B
- P/E
- 21.01
- P/S
- 5.10
- P/B
- 7.33
- EV/EBITDA
- 14.80
- Div Yield
- 3.12%
- Gross Margin
- 75.13%
- Op Margin
- 29.88%
- Net Margin
- 24.31%
- ROE
- 31.54%
- ROIC
- 14.89%
- Revenue
- $54.81B · 5.97%
- Net Income
- $14.06B · 17.71%
- EPS
- $7.25 · 22.47%
- Op Income
- $17.07B
- FCF YoY
- 28.11%
- 52W High
- $170.46
- 52W Low
- $112.34
- 50D MA
- $149.22
- 200D MA
- $141.28
- Beta
- 0.49
- Avg Volume
- 1.64M
Get TickerSpark's AI analysis on NVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NVS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on NVS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.